Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402442 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL28527138 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL29397673 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL31000548 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL29555721 | 0.91 | HDAC1 (0.57) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL377964 | 0.91 | HDAC1 (0.57) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL392598 | 0.91 | HDAC1 (0.57) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL15982313 | 0.91 | HDAC1 (0.57) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL16167663 | 0.90 | CTSK (0.47) | HDAC1HDAC2IDO1KMT2ATNF | |
| SCHEMBL18718108 | 0.90 | CASP3 (0.51) | HDAC1HDAC2IDO1KMT2AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878836-A1 | O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-09-15 | — | — | EP | disclosed |
| CN-112479933-A | Preparation method of N-fluorenylmethoxycarbonyl-3-chloro-alanine benzyl ester | 吉尔生化（上海）有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-9956296-B2 | Compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9937267-B2 | Methods of treating cancer using compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170266307-A1 | Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent | ELLIPSES PHARMA LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20160243252-A1 | COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT | ELLIPSES PHARMA LIMITED (GB) | 2016-08-25 | — | — | US | disclosed |
| US-9358303-B2 | Compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2016-06-07 | — | — | US | disclosed |
| EP-2481428-B1 | MMP activated vascular disrupting agents | INCANTHERA LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2134372-B1 | MMP ACTIVATED VASCULAR DISRUPTING AGENTS | INCANTHERA LTD (GB) | 2016-02-24 | — | — | EP | disclosed |
| EP-2010556-B1 | HOMOGENEOUS ERYTHROPOIETIN AND METHOD FOR THEIR PREPARATION | SLOAN KETTERING INST CANCER (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20150196658-A1 | Compounds | Incanthera Ltd. | 2015-07-16 | — | — | US | disclosed |
| US-8927486-B2 | Compounds | INCANTHERA LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20140179592-A1 | Compounds | INCANTHERA LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2481429-A2 | MMP Activated Vascular Disrupting Agents | University of Bradford (GB) | 2012-08-01 | — | — | EP | disclosed |
| EP-2481428-A2 | MMP activated vascular disrupting agents | University of Bradford (GB) | 2012-08-01 | — | — | EP | disclosed |
| US-20110275554-A1 | COMPOUNDS | THE UNIVERSITY OF BRADFORD (GB) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196658-A1 | Compounds | ADAM17, MMP3, MMP25 | HDAC1 780/4885HDAC2 1311/4885IDO1 2922/4885 |
| US-20170266307-A1 | Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent | MMP10, MMP25, MMP26 | HDAC1 468/4885HDAC2 812/4885IDO1 3594/4885 |
| US-20160243252-A1 | COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT | MMP10, MMP11, MMP3 | HDAC1 658/4885HDAC2 1514/4885IDO1 3516/4885 |
| US-20110275554-A1 | COMPOUNDS | ADAM17, MMP3, MMP25 | HDAC1 780/4885HDAC2 1311/4885IDO1 2922/4885 |
| US-20140179592-A1 | Compounds | MMP9, MMP3, MMP10 | HDAC1 498/4885HDAC2 820/4885IDO1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.